CAMBRIDGE, Mass. and TARRYTOWN, N.Y., June 19, 2020 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has approved a 300 mg single-dose pre-filled pen for Dupixent® (dupilumab). The ...

Please provide your email address to receive an email when new articles are posted on . The FDA has expanded approval of the single-dose Dupixent pre-filled pen for use in children aged as young as 2 ...

MISSISSAUGA, ON, June 17, 2021 /CNW/ - Sanofi Canada announced today that a new 300 mg single-dose (single-use) pre-filled pen for DUPIXENT ® (dupilumab injection) is now available in Canada. The ...

The FDA has approved a prefilled pen formulation of Dupixent (dupilumab; Sanofi and Regeneron), providing another option for administering the treatment. The Food and Drug Administration has approved ...

Please provide your email address to receive an email when new articles are posted on . The Dupixent prefilled pen has been approved by the FDA for all Dupixent indications in patients aged 12 years ...

If approved, Dupixent would be the first and only medicine indicated specifically for AFRS, which would be its ninth FDA-approved indication TARRYTOWN, N.Y. and PARIS, Nov. 07, 2025 (GLOBE NEWSWIRE) - ...

Dupixent (dupilumab) has been a breakthrough treatment for people with severe eczema, asthma, and other inflammatory conditions. For many, it has provided relief when other therapies failed. However, ...

Dupixent is a branded injectable medication doctors prescribe to treat eosinophilic esophagitis (EoE). Doctors usually prescribe 300 milligrams once per week. They mostly prescribe it to adults, but ...

Single-dose (300 mg) pre-filled pen provides additional administration option to adults and adolescents who are prescribed Dupixent 300 mg pre-filled pen expected to be available third quarter of 2020 ...

300 mg pre-filled pen expected to be available third quarter of 2020 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has ...